These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 34362853)

  • 61. Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis.
    Fu CC; Gao C; Zhang HH; Mao YQ; Lu JQ; Petritis B; Huang AS; Yang XG; Long YM; Huang RP
    Mult Scler Relat Disord; 2022 Mar; 59():103527. PubMed ID: 35172264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [The correlation factor analysis for conversion of clinically isolated syndrome to multiple sclerosis and neuromyelitis optica].
    Bi CF; Qian HR; Peng LJ; Mao LL; Huang X; Xia DY; Lei X; Qi XK
    Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):460-5. PubMed ID: 27256609
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy.
    Wang Y; Wu A; Chen X; Zhang L; Lin Y; Sun S; Cai W; Zhang B; Kang Z; Qiu W; Hu X; Lu Z
    BMC Neurol; 2014 Dec; 14():246. PubMed ID: 25526927
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
    Masuda H; Mori M; Uzawa A; Uchida T; Ohtani R; Kuwabara S
    PLoS One; 2020; 15(4):e0224419. PubMed ID: 32251416
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.
    van Rooij LC; Wattjes MP; de Jong BA; van Oosten BW
    Mult Scler Relat Disord; 2017 Oct; 17():54-56. PubMed ID: 29055475
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Motamedi S; Oertel FC; Yadav SK; Kadas EM; Weise M; Havla J; Ringelstein M; Aktas O; Albrecht P; Ruprecht K; Bellmann-Strobl J; Zimmermann HG; Paul F; Brandt AU
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32576604
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical presentations of neuromyelitis optica spectrum disorders with ultra-longitudinally extensive transverse myelitis].
    Huang X; Xu FF; Qian HR; Lei X; Qi XK; Xia DY
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(21):1658-1663. PubMed ID: 29925142
    [No Abstract]   [Full Text] [Related]  

  • 71. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transformer-Based Deep-Learning Algorithm for Discriminating Demyelinating Diseases of the Central Nervous System With Neuroimaging.
    Huang C; Chen W; Liu B; Yu R; Chen X; Tang F; Liu J; Lu W
    Front Immunol; 2022; 13():897959. PubMed ID: 35774780
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Kwak K; Hyun JW; Jeong IH; Jo HJ; Joung A; Kim JH; Lee SH; Yun S; Joo J; Lee JM; Kim HJ
    Eur J Neurol; 2016 Jul; 23(7):1165-73. PubMed ID: 27108769
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Liu Y; Dong D; Zhang L; Zang Y; Duan Y; Qiu X; Huang J; Dong H; Barkhof F; Hu C; Fang M; Tian J; Li K
    Eur Radiol; 2019 Sep; 29(9):4670-4677. PubMed ID: 30770971
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.
    Chen X; Peng Y; Zheng Q; Luo D; Han Y; Luo Q; Zhu Q; Luo T; Li Y
    Front Immunol; 2022; 13():1007335. PubMed ID: 36532033
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD.
    Carnero Contentti E; Delgado-García G; Criniti J; López PA; Pettinicchi JP; Cristiano E; Miguez J; Correa-Díaz EP; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Tkachuk V; Caride A; Rojas JI
    Front Immunol; 2021; 12():628024. PubMed ID: 33717149
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
    PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resolution of inflammation in neuromyelitis optica spectrum disorders.
    Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
    Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.